1 results found.

High Risk Acute Myeloid Leukemia Clinical Trial using CPX-351; 7+3 (cytarabine and daunorubicin)

Celator Pharmaceuticals - Recruiting 60 years to 75 years.
- Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age With Untreated High Risk (Secondary) AML.
CPX-351; 7+3 (cytarabine and daunorubicin)